Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers, which are added to most processed foods to aid texture and extend shelf life, can alter the gut microbiota composition and localization to induce intestinal inflammation that promotes the development of inflammatory bowel disease and metabolic syndrome, new research shows.

26 Feb 2015

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars.

26 Feb 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.

26 Feb 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.

25 Feb 2015

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

23 Feb 2015

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

23 Feb 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse.

23 Feb 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.

19 Feb 2015

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Inflammatory bowel diseases (IBDs), including Crohn disease and ulcerative colitis, are hard to completely cure. Globally, IBDs affect more than 4 million people, today. However, Professor Soichi Tanabe (Graduate School of Biosphere Science, Hiroshima University) and his collaborators have demonstrated that 10-hydroxy-cis-12-octadecenoic acid (HYA), a gut microbial metabolite of linoleic acid, has a suppressive effect on intestinal inflammation.

19 Feb 2015

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Cells lining the intestinal tract form a critical barrier, protecting our bodies from the billions of bacteria living in the gut. Breaches in this barrier are driven largely by a single signaling molecule called tumor necrosis factor (TNF), elevated amounts of which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

17 Feb 2015

Bacteria's DNA can pass trait to offspring in a way similar to parents' own DNA

It's a firmly established fact straight from Biology 101: Traits such as eye color and height are passed from one generation to the next through the parents' DNA.

17 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

OSU researchers discover impact of antibiotics on microorganisms that live in animal's gut

Researchers at Oregon State University have discovered that antibiotics have an impact on the microorganisms that live in an animal's gut that's more broad and complex than previously known.

11 Feb 2015

New study shows that chronic narcotic use more prevalent in children with IBD

Chronic narcotic use is more than twice as prevalent in children with inflammatory bowel disease (IBD), compared with children without this disease, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

10 Feb 2015

Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Its name is daunting. It's the hottest topic among allergy experts. It's showing up more and doctors don't yet know why. Allergy specialists at The Ohio State University Wexner Medical Center are seeing more people with eosinophilic esophagitis (EoE), an inflammatory response in the esophagus that makes it hard to swallow food.

9 Feb 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.

31 Jan 2015

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Scientists find new links between inflammation and tissue regeneration

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Actavis files ANDA to market Budesonide Extended-release Tablets

Shire announces acquisition of Meritage Pharma

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Bacteria's DNA can pass trait to offspring in a way similar to parents' own DNA

Hospira announces launch of first biosimilar monoclonal antibody in Europe

OSU researchers discover impact of antibiotics on microorganisms that live in animal's gut

New study shows that chronic narcotic use more prevalent in children with IBD

Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in